References
1. Autism spectrum disorders. URL: https://www.who.int/mediacentre/factsheets/autism-spectrum disorders/ru (date of access June 6, 2018)
2. Vinogradova K.N. Etiology of autistic spectrum disorders. Sovremennaya zarubezhnaya psikhologiya [Modern Foreign Psychology]. 2014; 3 (4): 112–31. (in Russian)
3. Bavykina I.A., Zvyagin A.A., Nastausheva T.L. gluten Intolerance and autism spectrum disorders: a pathological tandem? Voprosy detskoy dietologii [Problems of Pediatric Nutrition]. 2017; 15 (2): 42–4. DOI: https://doi.org/10.20953/1727-5784-2017-2-42-44. (in Russian)
4. Zvyagin A.A., Bavykina I.A.. Nutritional approaches in treatment of autism spectrum disorders in children. Pediatriya. Zhurnal imeni G.N. Speranskogo [Pediatrics. Journal named after G.N. Speransky]. 2019; 98 (6): 171–6. DOI: https://doi.org/10.24110/0031-403X-2019-98-6-171-176 (in Russian)
5. Degterev D.А., Damulin I.V., Parfenov A.I. Neurological disorders associated with gluten sensitivity. Terapevticheskiy arkhiv [Therapeutic Archive]. 2017; 89 (2): 99–102. DOI: https://doi.org/10.17116/terarkh201789299-102 (in Russian)
6. Ivanova D.V., Semina I.I., Ziganshin A.U. Somatic disorders in autism as one of the factors of behavior and social interaction disorders. Kazanskiy meditsinskiy zhurnal [Kazan Medical Journal]. 2019; 100 (4): 689–94. DOI: https://doi.org/10.17816/kmj2019-689 (in Russian)
7. Chesnokova E.A., Sarycheva N.Yu., Dubynin V.A., Kamensky A.A. Opioid peptides obtained with food and their influence on the nervous system. Uspekhi fiziologicheskikh nauk [Advances in the Physiological Sciences]. 2015; 46 (1): 22–46. (in Russian)
8. Trivedi M.S., Shah J.S., Mughairy S.A., Hodgson N.W., Simms B., et al. Food-derived opioid peptides inhibit cysteine uptake with redox and epigenetic consequences. J Nutr Biochem. 2014; 25 (10): 1011–8. DOI: https://doi.org/10.1016/j.jnutbio.2014.05.004
9. Poletaev A.B., Poletaeva A.A., Khmel’nitskaya A.V. Changes in the opiate system in children suffering from autism. possible causes and consequences. Klinicheskaya patofiziologiya [Clinical Pathophysiology] 2016; 22 (1): 48–54. (in Russian)
10. Sun Z., Cade R. Findings in normal rats following administration of gliadorphin-7 (GD-7). Peptides. 2003; 24 (2): 321–4. DOI: https://doi.org/10.1016/s0196-9781(03)00043-3
11. Sun Z., Cade J.R., Fregly M.J., Privette R.M. β-Casomorphin induces fos-like immunoreactivity in discrete brain regions relevant to schizophrenia and autism. Autism. 1999; 3 (1): 67–83. DOI: https://doi.org/10.1177/1362361399003001006
12. Sokolov O.Yu., Kost N.V., Andreeva O.O., Korneeva E.V., Meshavkin V.K., Tarakanova Yu.N., et al. Possible role of casomorphins in the pathogenesis of autism. Psikhiatriya [Psychiatry]. 2010; (3): 29–35. (in Russian)
13. Jarmołowska B., Bukało M., Fiedorowicz E., Cieślińska A., Kordulewska N.K., Moszyńska M., et al. Role of milk-derived opioid peptides and proline dipeptidyl peptidase-4 in autism spectrum disorders. Nutrients. 2019; 11 (1): 87. DOI: https://doi.org/10.3390/nu11010087
14. Hunter L.C., O’Hare A., Herron W.J., Fisher L.A., Jones G.E. Opioid peptides and dipeptidyl peptidase in autism. Dev Med Child Neurol. 2003; 45 (2): 121–8. PMID: 12578238.
15. D’Eufemia P., Celli M., Finocchiaro R., Pacifico L., Viozzi L., Zaccagnini M., et al. Abnormal intestinal permeability in children with autism. Acta Paediatr. 1996; 85 (9): 1076–9. DOI: https://doi.org/10.1111/j.1651-2227.1996.tb14220.x
16. Khavkin A.I., Zhirnova S.А., Novikova V.P. The biological and clinical role of intestinal fatty acid-binding protein in clinical practice. Voprosy detskoy dietologii [Problems of Pediatric Nutrition]. 2020; 18 (1): 56–62. DOI: https://doi.org/10.20953/1727-5784-2020-1-56-62 (in Russian)
17. Zvyagin A.A., Bavykina I.A., Nastausheva T.L., Bavykin D.V. Intestinal fatty acid binding protein as the promising marker of small intestine permeability. Rossiyskiy vestnik perinatologii i pediatrii [Russian Bulletin of Perinatology and Pediatrics]. 2020; 65 (6): 29–33. DOI: https://doi.org/10.21508/10274065-2020-65-6-29-33 (in Russian)
18. Vreugdenhil A.C., Wolters V.M., Adriaanse M.P., Van den Neucker A.M., van Bijnen A.A., Houwen R., et al. Additional value of serum I-FABP levels for evaluating celiac disease activity in children. Scand J Gastroenterol. 2011; 46 (12): 1435–41. DOI: https://doi.org/10.3109/00365521.2011.627447
19. Adriaanse M.P., Tack G.J., Passos V.L., Damoiseaux J.G., Schreurs M.W., van Wijck K., et al. Serum I-FABP as marker for enterocyte damage in coeliac disease and its relation to villous atrophy and circulating autoantibodies. Aliment Pharmacol Ther. 2013; 37 (4): 482–90. DOI: https://doi.org/10.3109/00365521.2011.627447
20. Adriaanse M.P.M., Mubarak A., Riedl R.G., Ten Kate F.J.W., Damoiseaux J.G.M.C., Buurman W.A., et al.; Celiac Disease Study Group. Progress towards non-invasive diagnosis and follow-up of celiac disease in children; a prospective multicentre study to the usefulness of plasma I-FABP. Sci Rep. 2017; 7 (1): 8671. DOI: https://doi.org/10.1038/s41598-017-07242-4
21. Rubenstein E., Schieve L., Bradley C., DiGuiseppi C., Moody E., Thomas K., et al. The prevalence of gluten free diet uses among preschool children with autism spectrum disorder. Autism Res. 2018; 11 (1): 185–93. DOI: https://doi.org/10.1002/aur.1896
22. Ghalichi F., Ghaemmaghami J., Malek A., Ostadrahimi A. Effect of gluten free diet on gastrointestinal and behavioral indices for children with autism spectrum disorders: a randomized clinical trial. World J Pediatr. 2016; 12 (4): 436–42. DOI: https://doi.org/10.1007/s12519-016-0040-z
23. De Magistris L., Familiari V., Pascotto A., Sapone A., Frolli A., Iardino P., et al. Alterations of the intestinal barrier in patients with autism spectrum disorders and in their first-degree relatives. J Pediatr Gastroenterol Nutr. 2010; 51: 418–24. DOI: https://doi.org/10.1097/MPG.0b013e3181dcc4a5
24. Wang X., Niu Y., Yue C.X., Fu S., Wang R.T. Increased ileal bile acid binding protein and galectin-9 are associated with mild cognitive impairment and Alzheimer’s disease. J Psychiatr Res. 2019; 119: 102–6. DOI: https://doi.org/10.1016/j.jpsychires.2019.10.002/